Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 114 articles:
HTML format

Single Articles

    March 2023
  1. TAU S, Miller TW
    Alpelisib Efficacy without Cherry-PI3King Mutations.
    Clin Cancer Res. 2023;29:989-990.
    PubMed     Abstract available

  2. SIVAKUMAR S, Jin DX, Rathod R, Ross J, et al
    Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.
    Clin Cancer Res. 2023;29:1125-1136.
    PubMed     Abstract available

  3. RUGO HS, Raskina K, Schrock AB, Madison RW, et al
    Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.
    Clin Cancer Res. 2023;29:1056-1067.
    PubMed     Abstract available

    February 2023
  4. GRAESER M, Gluz O, Biehl C, Ulbrich-Gebauer D, et al
    Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
    Clin Cancer Res. 2023;29:805-814.
    PubMed     Abstract available

  5. GUERRERO-ZOTANO A, Belli S, Zielinski C, Gil-Gil M, et al
    CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer.
    Clin Cancer Res. 2023 Feb 7:CCR-22-2206. doi: 10.1158/1078-0432.CCR-22-2206.
    PubMed     Abstract available

  6. IQBAL R, Yaqub M, Bektas HO, Oprea-Lager DE, et al
    [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
    Clin Cancer Res. 2023 Feb 3:CCR-22-2720. doi: 10.1158/1078-0432.CCR-22-2720.
    PubMed     Abstract available

  7. DENKERT C, Lambertini C, Fasching PA, Pogue-Geile KL, et al
    Biomarker Data From the Phase III KATHERINE Study of Adjuvant T-DM1 Versus Trastuzumab for Residual Invasive Disease After Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Clin Cancer Res. 2023 Feb 2:CCR-22-1989. doi: 10.1158/1078-0432.CCR-22-1989.
    PubMed     Abstract available

    January 2023
  8. ARPINO G, de la Haba-Rodriguez J, Ferrero JM, De Placido S, et al
    Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis.
    Clin Cancer Res. 2023 Jan 30:CCR-22-1092. doi: 10.1158/1078-0432.CCR-22-1092.
    PubMed     Abstract available

  9. JENKINS S, Zhang W, Steinberg SM, Nousome D, et al
    Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
    Clin Cancer Res. 2023 Jan 27:CCR-22-0855. doi: 10.1158/1078-0432.CCR-22-0855.
    PubMed     Abstract available

  10. DAVIS AA, Luo J, Zheng T, Dai C, et al
    Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.
    Clin Cancer Res. 2023 Jan 24:CCR-22-2177. doi: 10.1158/1078-0432.CCR-22-2177.
    PubMed     Abstract available

  11. NEDERLOF I, Voorwerk L, Kok M
    Facts and hopes in immunotherapy for early-stage triple-negative breast cancer.
    Clin Cancer Res. 2023 Jan 9:CCR-22-0701. doi: 10.1158/1078-0432.CCR-22-0701.
    PubMed     Abstract available

    December 2022
  12. RONCHI C, Brisken C
    Targeting the progesterone receptor in breast cancer: mind the short form!
    Clin Cancer Res. 2022 Dec 22:CCR-22-3374. doi: 10.1158/1078-0432.CCR-22-3374.
    PubMed     Abstract available

  13. VISVANATHAN K, Cope L, Fackler MJ, Considine M, et al
    Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
    Clin Cancer Res. 2022 Dec 19:CCR-22-2128. doi: 10.1158/1078-0432.CCR-22-2128.
    PubMed     Abstract available

  14. ROBERTSON JFR, Coleman RE, Cheung KL, Evans A, et al
    Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
    Clin Cancer Res. 2022;28:5469.

  15. ROELOFS PA, Martens JWM, Harris RS, Span PN, et al
    Clinical Implications of APOBEC3-mediated Mutagenesis in Breast Cancer.
    Clin Cancer Res. 2022 Dec 8:CCR-22-2861. doi: 10.1158/1078-0432.CCR-22-2861.
    PubMed     Abstract available

    November 2022
  16. MATIKAS A, Johansson H, Gryback P, Bjohle J, et al
    Survival outcomes, digital TILs and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial.
    Clin Cancer Res. 2022 Nov 30:CCR-22-2829. doi: 10.1158/1078-0432.CCR-22-2829.
    PubMed     Abstract available

  17. PIETRANTONIO F, Manca P, Bellomo SE, Corso S, et al
    HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial.
    Clin Cancer Res. 2022 Nov 22:CCR-22-2533. doi: 10.1158/1078-0432.CCR-22-2533.
    PubMed     Abstract available

  18. ASLEH K, Lluch A, Goytain A, Barrios C, et al
    Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine.
    Clin Cancer Res. 2022 Nov 8. pii: 710523. doi: 10.1158/1078-0432.CCR-22-2191.
    PubMed     Abstract available

    October 2022
  19. SOFFIETTI R, Pellerino A
    Brain metastasis from HER2-positive breast cancer: an evolving landscape.
    Clin Cancer Res. 2022 Oct 28. pii: 710102. doi: 10.1158/1078-0432.CCR-22-2853.
    PubMed     Abstract available

  20. ELIA A, Saldain L, Vanzulli SI, Helguero LA, et al
    Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial.
    Clin Cancer Res. 2022 Oct 21. pii: 709943. doi: 10.1158/1078-0432.CCR-22-2060.
    PubMed     Abstract available

  21. GAZINSKA P, Milton C, Iacovacci J, Ward J, et al
    Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
    Clin Cancer Res. 2022;28:4494-4508.
    PubMed     Abstract available

  22. TSUJI J, Li T, Grinshpun A, Coorens T, et al
    Clinical Efficacy and Whole Exome Sequencing of Liquid Biopsies in a Phase IB/II study of Bazedoxifene and Palbociclib in Hormone Receptor-Positive Breast Cancer.
    Clin Cancer Res. 2022 Oct 10. pii: 709684. doi: 10.1158/1078-0432.CCR-22-2305.
    PubMed     Abstract available

    September 2022
  23. ALBANELL J, Perez-Garcia JM, Gil-Gil M, Curigliano G, et al
    Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
    Clin Cancer Res. 2022 Sep 27. pii: 709486. doi: 10.1158/1078-0432.CCR-22-1281.
    PubMed     Abstract available

  24. PLYM A, Zhang Y, Stopsack KH, Jee YH, et al
    Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years.
    Clin Cancer Res. 2022 Sep 14. pii: 709205. doi: 10.1158/1078-0432.CCR-22-1723.
    PubMed     Abstract available

  25. SHARMA P
    Time to optimize de-escalation strategies in triple-negative breast cancer?
    Clin Cancer Res. 2022 Sep 9. pii: 709144. doi: 10.1158/1078-0432.CCR-22-2140.
    PubMed     Abstract available

  26. KABRAJI S, Ni J, Sammons S, Li T, et al
    Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases.
    Clin Cancer Res. 2022 Sep 8. pii: 709125. doi: 10.1158/1078-0432.CCR-22-1138.
    PubMed     Abstract available

  27. FOLDI J, Kahn A, Silber A, Qing T, et al
    Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
    Clin Cancer Res. 2022;28:3720-3728.
    PubMed     Abstract available

  28. HU C, Susswein LR, Roberts ME, Yang H, et al
    Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
    Clin Cancer Res. 2022;28:3742-3751.
    PubMed     Abstract available

  29. BATALINI F, Gulhan DC, Mao V, Tran A, et al
    Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    Clin Cancer Res. 2022 Sep 1. pii: 708955. doi: 10.1158/1078-0432.CCR-22-0749.
    PubMed     Abstract available

    August 2022
  30. CONSTANTINIDOU A, Marcou Y, Toss MS, Simmons T, et al
    Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer.
    Clin Cancer Res. 2022 Aug 31. pii: 708058. doi: 10.1158/1078-0432.CCR-22-0619.
    PubMed     Abstract available

  31. CRISTOFANILLI M, Rugo HS, Im SA, Slamon DJ, et al
    Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
    Clin Cancer Res. 2022;28:3433-3442.
    PubMed     Abstract available

  32. SHAH M, Osgood CL, Amatya AK, Fiero MH, et al
    FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple Negative Breast Cancer.
    Clin Cancer Res. 2022 Aug 4. pii: 707438. doi: 10.1158/1078-0432.CCR-22-1110.
    PubMed     Abstract available

  33. SINGER CF, Holst F, Steurer S, Burandt EC, et al
    Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
    Clin Cancer Res. 2022 Aug 3:OF1-OF9. doi: 10.1158/1078-0432.CCR-21-4328.
    PubMed     Abstract available

    July 2022
  34. SUN K, Xu Y, Zhang L, Niravath P, et al
    A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2022 Jul 25. pii: 707209. doi: 10.1158/1078-0432.CCR-22-0622.
    PubMed     Abstract available

  35. GLUZ O, Nitz U, Kolberg-Liedtke C, Prat A, et al
    De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial.
    Clin Cancer Res. 2022 Jul 7. pii: 706903. doi: 10.1158/1078-0432.CCR-22-0482.
    PubMed     Abstract available

  36. SALGADO R, Loi S
    What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet.
    Clin Cancer Res. 2022;28:2728-2729.
    PubMed     Abstract available

    June 2022
  37. ZHANG J, Ji D, Shen W, Xiao Q, et al
    Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2022 Jun 29:OF1-OF10. doi: 10.1158/1078-0432.CCR-22-0456.
    PubMed     Abstract available

  38. KUMAR T, Hobbs E, Yang F, Chang JT, et al
    Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation.
    Clin Cancer Res. 2022 Jun 23. pii: 705099. doi: 10.1158/1078-0432.CCR-21-1278.
    PubMed     Abstract available

  39. LI J, Jiang J, Bao X, Kumar V, et al
    Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases.
    Clin Cancer Res. 2022 Jun 21:OF1-OF13. doi: 10.1158/1078-0432.CCR-22-0405.
    PubMed     Abstract available

  40. YIN W, Wang Y, Wu Z, Ye Y, et al
    Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
    Clin Cancer Res. 2022 Jun 17. pii: 704938. doi: 10.1158/1078-0432.CCR-22-0446.
    PubMed     Abstract available

  41. XIA Y, He X, Renshaw L, Martinez-Perez C, et al
    Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer.
    Clin Cancer Res. 2022 Jun 2. pii: 699314. doi: 10.1158/1078-0432.CCR-21-3189.
    PubMed     Abstract available

  42. FASCHING PA, Liu D, Scully S, Ingle JN, et al
    Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Breast Cancer Patients.
    Clin Cancer Res. 2022 Jun 2. pii: 699313. doi: 10.1158/1078-0432.CCR-20-4774.
    PubMed     Abstract available

  43. SUMAN VJ, Du L, Hoskin T, Anurag M, et al
    Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031).
    Clin Cancer Res. 2022 Jun 2. pii: 699315. doi: 10.1158/1078-0432.CCR-22-0068.
    PubMed     Abstract available

  44. BYCHKOVSKY BL, Li T, Sotelo J, Tayob N, et al
    Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    Clin Cancer Res. 2022;28:2349-2360.
    PubMed     Abstract available

    May 2022
  45. ZHANG J, Ji D, Shen W, Xiao Q, et al
    Phase I Trial of a Novel Anti-HER2 Antibody-drug Conjugate, ARX788, for the Treatment of HER2-positive Metastatic Breast Cancer.
    Clin Cancer Res. 2022 May 26. pii: 699249. doi: 10.1158/1078-0432.CCR-22-0456.
    PubMed     Abstract available

  46. LINDEMAN GJ, Fernando TM, Bowen R, Jerzak KJ, et al
    VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, Biomarker Results.
    Clin Cancer Res. 2022 May 18. pii: 699022. doi: 10.1158/1078-0432.CCR-21-3811.
    PubMed     Abstract available

  47. BONI V, Fidler MJ, Arkenau HT, Spira A, et al
    Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
    Clin Cancer Res. 2022;28:2020-2029.
    PubMed     Abstract available

  48. DMELLO C, Sonabend A, Arrieta VA, Zhang DY, et al
    Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma.
    Clin Cancer Res. 2022 May 12. pii: 698878. doi: 10.1158/1078-0432.CCR-21-2563.
    PubMed     Abstract available

  49. RADOVICH M, Solzak JP, Wang CJ, Hancock BA, et al
    Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer.
    Clin Cancer Res. 2022 May 12. pii: 698879. doi: 10.1158/1078-0432.CCR-21-3078.
    PubMed     Abstract available

  50. COLEMAN IM, DeSarkar N, Morrissey C, Xin L, et al
    Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2022 May 12. pii: 698880. doi: 10.1158/1078-0432.CCR-21-4289.
    PubMed     Abstract available

  51. YAM C, Abuhadra N, Sun R, Adrada BE, et al
    Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer.
    Clin Cancer Res. 2022 May 4. pii: 696297. doi: 10.1158/1078-0432.CCR-21-3100.
    PubMed     Abstract available

    April 2022
  52. TOLANEY SM, Toi M, Neven P, Sohn J, et al
    Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
    Clin Cancer Res. 2022;28:1500-1506.
    PubMed     Abstract available

  53. BLENMAN KRM, Marczyk M, Karn T, Qing T, et al
    Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer.
    Clin Cancer Res. 2022 Apr 4. pii: 694190. doi: 10.1158/1078-0432.CCR-21-3215.
    PubMed     Abstract available

  54. LIM JSJ, Wong ALA, Ow SGW, Ngoi NYL, et al
    Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694118. doi: 10.1158/1078-0432.CCR-21-4179.
    PubMed     Abstract available

  55. WESTPHALEN CB, Fine AD, Andre F, Ganesan S, et al
    Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Clin Cancer Res. 2022;28:1412-1421.
    PubMed     Abstract available

    March 2022
  56. YEHIA L, Eng C
    One Size Does Not Fit All: Breast Cancer in Young Women.
    Clin Cancer Res. 2022 Mar 23. pii: 688107. doi: 10.1158/1078-0432.CCR-22-0352.
    PubMed     Abstract available

  57. BERGAMINO MA, Morani G, Parker J, Schuster EF, et al
    Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.
    Clin Cancer Res. 2022;28:1217-1228.
    PubMed     Abstract available

  58. VIGANO L, Locatelli A, Ulisse A, Galbardi B, et al
    Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer.
    Clin Cancer Res. 2022 Mar 7. pii: 682079. doi: 10.1158/1078-0432.CCR-21-3185.
    PubMed     Abstract available

  59. CHEN L, Jiang YZ, Wu SY, Wu J, et al
    Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial.
    Clin Cancer Res. 2022 Mar 3. pii: 681997. doi: 10.1158/1078-0432.CCR-21-4313.
    PubMed     Abstract available

    February 2022
  60. LENOUE-NEWTON ML, Chen SC, Stricker T, Hyman DM, et al
    Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE.
    Clin Cancer Res. 2022 Feb 18. pii: 681702. doi: 10.1158/1078-0432.CCR-21-0885.
    PubMed     Abstract available

  61. BUNDRED N, Porta N, Brunt AM, Cramer A, et al
    Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
    Clin Cancer Res. 2022 Feb 14. pii: 1078-0432.CCR-21-3177.
    PubMed     Abstract available

  62. BATALINI F, Xiong N, Tayob N, Polak M, et al
    Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
    Clin Cancer Res. 2022 Feb 11. pii: 1078-0432.CCR-21-3045.
    PubMed     Abstract available

  63. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study.
    Clin Cancer Res. 2022 Feb 10. pii: 1078-0432.CCR-21-3385.
    PubMed     Abstract available

  64. KURANI H, Razavipour SF, Harikumar KB, Dunworth M, et al
    DOT1L is a novel cancer stem cell target for triple negative breast cancer.
    Clin Cancer Res. 2022 Feb 8. pii: 1078-0432.CCR-21-1299.
    PubMed     Abstract available

  65. PEDDI PF, Fasching PA, Liu D, Quinaux E, et al
    Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.
    Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-1762.
    PubMed     Abstract available

    January 2022
  66. WAKS AG, Kim D, Jain E, Snow C, et al
    Somatic and germline genomic alterations in very young women with breast cancer.
    Clin Cancer Res. 2022 Jan 31. pii: 1078-0432.CCR-21-2572.
    PubMed     Abstract available

  67. BLUM JL, Laird AD, Litton JK, Rugo HS, et al
    Determinants of Response to Talazoparib in Patients with HER2-negative, Germline BRCA1/2-mutated Breast Cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-2080.
    PubMed     Abstract available

  68. MA CX, Luo J, Freedman RA, Pluard TJ, et al
    The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3418.
    PubMed     Abstract available

  69. SCHWARTZ CJ, da Silva EM, Marra A, Gazzo AM, et al
    Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
    Clin Cancer Res. 2022;28:404-413.
    PubMed     Abstract available

  70. GARCIA-SAENZ JA, Martinez-Janez N, Cubedo R, Jerez Y, et al
    Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor.
    Clin Cancer Res. 2022 Jan 3. pii: 1078-0432.CCR-21-2652.
    PubMed     Abstract available

    December 2021
  71. KESTER L, Seinstra D, van Rossum AGJ, Vennin C, et al
    Differential survival and therapy benefit of breast cancer patients are characterized by distinct epithelial and immune cell microenvironments.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1442.
    PubMed     Abstract available

  72. LU YS, Im SA, Colleoni M, Franke F, et al
    Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-3032.
    PubMed     Abstract available

  73. FITZPATRICK A, Iravani M, Mills A, Childs L, et al
    Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3017.
    PubMed     Abstract available

  74. ROYCE M, Osgood CL, Amatya AK, Fiero MH, et al
    FDA Approval Summary: Margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer.
    Clin Cancer Res. 2021 Dec 16. pii: 1078-0432.CCR-21-3247.
    PubMed     Abstract available

  75. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
    Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
    Clin Cancer Res. 2021;27:6815-6823.
    PubMed     Abstract available

  76. SHI Z, Wulfkuhle J, Nowicka M, Gallagher RI, et al
    Functional Mapping of AKT Signaling and Biomarkers of Response From the FAIRLANE Trial of Neoadjuvant Ipatasertib Plus Paclitaxel for Triple-Negative Breast Cancer.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-2498.
    PubMed     Abstract available

  77. TAN AR, Wright GS, Thummala AR, Danso MA, et al
    Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study.
    Clin Cancer Res. 2021 Dec 9. pii: 1078-0432.CCR-21-2272.
    PubMed     Abstract available

  78. ZHOU Q, Gampenrieder SP, Frantal S, Rinnerthaler G, et al
    Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response.
    Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-3231.
    PubMed     Abstract available

  79. ATRAFI F, Boix O, Subbiah V, Diamond JR, et al
    A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
    Clin Cancer Res. 2021;27:6366-6375.
    PubMed     Abstract available

    November 2021
  80. MOORE HCF, Barlow WE, Somlo G, Gralow JR, et al
    A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3131.
    PubMed     Abstract available

  81. ZHANG J, Ji D, Cai L, Yao H, et al
    First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-2827.
    PubMed     Abstract available

  82. HUA X, Bi XW, Zhao JL, Shi YX, et al
    Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002).
    Clin Cancer Res. 2021 Nov 22. pii: 1078-0432.CCR-21-3435.
    PubMed     Abstract available

  83. NIE P, Kalidindi T, Nagle VL, Wu X, et al
    Imaging of Cancer gamma-Secretase Activity Using an Inhibitor-Based PET Probe.
    Clin Cancer Res. 2021;27:6145-6155.
    PubMed     Abstract available

  84. LLOYD MR, Spring LM, Bardia A, Wander SA, et al
    Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities.
    Clin Cancer Res. 2021 Nov 1. pii: 1078-0432.CCR-21-2947.
    PubMed     Abstract available

  85. SARDESAI SD, Thomas A, Gallagher C, Lynce F, et al
    Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.
    Clin Cancer Res. 2021;27:5810-5817.
    PubMed     Abstract available

    October 2021
  86. ADAMS S, Othus M, Patel SP, Miller KD, et al
    A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
    Clin Cancer Res. 2021 Oct 29. pii: 1078-0432.CCR-21-2182.
    PubMed     Abstract available

  87. ARORA S, Narayan P, Osgood CL, Wedam S, et al
    U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
    Clin Cancer Res. 2021 Oct 28. pii: 1078-0432.CCR-21-2600.
    PubMed     Abstract available

  88. DIECI MV, Guarneri V, Tosi A, Bisagni G, et al
    Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2260.
    PubMed     Abstract available

    Interpreting the Complex Landscape of Immune-Tumor Interface.
    Clin Cancer Res. 2021;27:5446-5448.
    PubMed     Abstract available

  90. VENET D, Rediti M, Maetens M, Fumagalli D, et al
    Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
    Clin Cancer Res. 2021;27:5607-5618.
    PubMed     Abstract available

  91. ELKHOLI IE, Foulkes WD, Rivera B
    MRN Complex and Cancer Risk: Old Bottles, New Wine.
    Clin Cancer Res. 2021;27:5465-5471.
    PubMed     Abstract available

  92. DOWSETT M, Kilburn L, Rimawi MF, Osborne CK, et al
    Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1628.
    PubMed     Abstract available

  93. ASLEH K, Tu D, Gao D, Bramwell V, et al
    Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials.
    Clin Cancer Res. 2021 Oct 6. pii: 1078-0432.CCR-21-1942.
    PubMed     Abstract available

  94. KUEMMEL S, Campone M, Loirat D, Lopez Lopez R, et al
    A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer.
    Clin Cancer Res. 2021 Oct 6. pii: 1078-0432.CCR-20-3955.
    PubMed     Abstract available

  95. THORAT MA, Levey PM, Jones JL, Pinder SE, et al
    Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.
    Clin Cancer Res. 2021;27:5317-5324.
    PubMed     Abstract available

    September 2021
  96. SANCHEZ-GUIXE M, Hierro C, Jimenez J, Viaplana C, et al
    High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1810.
    PubMed     Abstract available

  97. SCHOUTEN PC, Richters LK, Vis DJ, Kommoss S, et al
    Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1673.
    PubMed     Abstract available

  98. PUHALLA SL, Dieras V, Arun BK, Kaufman B, et al
    Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
    Clin Cancer Res. 2021;27:4983-4993.
    PubMed     Abstract available

  99. WESTIN SN, Labrie M, Litton JK, Blucher A, et al
    Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-1656.
    PubMed     Abstract available

    August 2021
  100. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    PubMed     Abstract available

    July 2021
  101. BLEACH R, Madden SF, Hawley J, Charmsaz S, et al
    Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy.
    Clin Cancer Res. 2021;27:3980-3989.
    PubMed     Abstract available

  102. DECENSI A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, et al
    Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease.
    Clin Cancer Res. 2021;27:3576-3583.
    PubMed     Abstract available

    June 2021
  103. STRELL C, Folkvaljon D, Holmberg E, Schiza A, et al
    High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial.
    Clin Cancer Res. 2021;27:3469-3477.
    PubMed     Abstract available

  104. COMPTE M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, et al
    An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
    Clin Cancer Res. 2021;27:3167-3177.
    PubMed     Abstract available

    May 2021
  105. THORAT MA, Levey PM, Jones JL, Pinder SE, et al
    Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial.
    Clin Cancer Res. 2021;27:2861-2867.
    PubMed     Abstract available

  106. TELLI ML, Nagata H, Wapnir I, Acharya CR, et al
    Intratumoral Plasmid IL12 Expands CD8(+) T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.
    Clin Cancer Res. 2021;27:2481-2493.
    PubMed     Abstract available

    April 2021
  107. HONG DS, Moore KN, Bendell JC, Karp DD, et al
    Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
    Clin Cancer Res. 2021;27:1864-1874.
    PubMed     Abstract available

  108. CLAUSER P, Krug B, Bickel H, Dietzel M, et al
    Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy.
    Clin Cancer Res. 2021;27:1941-1948.
    PubMed     Abstract available

    March 2021
  109. ZHAO M, Scott S, Evans KW, Yuca E, et al
    Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Clin Cancer Res. 2021;27:1681-1694.
    PubMed     Abstract available

    February 2021
  110. LIU CC, Veeraraghavan J, Tan Y, Kim JA, et al
    A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers.
    Clin Cancer Res. 2021;27:785-798.
    PubMed     Abstract available

    October 2020
  111. WAHDAN-ALASWAD RS, Edgerton SM, Salem H, Kim H, et al
    Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2647.
    PubMed     Abstract available

    August 2020
  112. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
    Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
    PubMed     Abstract available

    July 2020
  113. TOLANEY SM, Sahebjam S, Le Rhun E, Bachelot T, et al
    A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1764.
    PubMed     Abstract available

    January 2020
  114. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
    ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.